DE60216959D1 - Sich in schlagende kardiomyozyten verwandelnde stammzellen - Google Patents

Sich in schlagende kardiomyozyten verwandelnde stammzellen

Info

Publication number
DE60216959D1
DE60216959D1 DE60216959T DE60216959T DE60216959D1 DE 60216959 D1 DE60216959 D1 DE 60216959D1 DE 60216959 T DE60216959 T DE 60216959T DE 60216959 T DE60216959 T DE 60216959T DE 60216959 D1 DE60216959 D1 DE 60216959D1
Authority
DE
Germany
Prior art keywords
cardiomyocytes
stem cells
bangken
cells
spoc cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60216959T
Other languages
English (en)
Inventor
D Epstein
V Gopal
O Winitsky
Shahin Hassanzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60216959D1 publication Critical patent/DE60216959D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
DE60216959T 2001-10-22 2002-10-22 Sich in schlagende kardiomyozyten verwandelnde stammzellen Expired - Lifetime DE60216959D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/003,400 US20030082153A1 (en) 2001-10-22 2001-10-22 Stem cells that transform to beating cardiomyocytes
PCT/US2002/033860 WO2003035838A2 (en) 2001-10-22 2002-10-22 Stem cells that transform to beating cardiomyocytes

Publications (1)

Publication Number Publication Date
DE60216959D1 true DE60216959D1 (de) 2007-02-01

Family

ID=21705682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216959T Expired - Lifetime DE60216959D1 (de) 2001-10-22 2002-10-22 Sich in schlagende kardiomyozyten verwandelnde stammzellen

Country Status (8)

Country Link
US (3) US20030082153A1 (de)
EP (1) EP1444329B1 (de)
JP (1) JP4377690B2 (de)
AT (1) ATE348878T1 (de)
AU (1) AU2002337949B1 (de)
CA (1) CA2464088A1 (de)
DE (1) DE60216959D1 (de)
WO (1) WO2003035838A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42643E1 (en) 1991-03-27 2011-08-23 Panasonic Corporation Communication system
USRE39890E1 (en) 1991-03-27 2007-10-23 Matsushita Electric Industrial Co., Ltd. Communication system
USRE40241E1 (en) 1991-03-27 2008-04-15 Matsushita Electric Industrial Co., Ltd. Communication system
CA2332405C (en) * 1992-03-26 2007-01-23 Matsushita Electric Industrial Co., Ltd. Communication system
US6724976B2 (en) * 1992-03-26 2004-04-20 Matsushita Electric Industrial Co., Ltd. Communication system
US6728467B2 (en) * 1992-03-26 2004-04-27 Matsushita Electric Industrial Co., Ltd. Communication system
USRE38513E1 (en) 1992-03-26 2004-05-11 Matsushita Electric Industrial Co., Ltd. Communication system
US7158577B1 (en) 1992-03-26 2007-01-02 Matsushita Electric Industrial Co., Ltd. Communication system
US5802241A (en) 1992-03-26 1998-09-01 Matsushita Electric Industrial Co., Ltd. Communication system
US7894541B2 (en) * 1992-03-26 2011-02-22 Panasonic Corporation Communication system
US7166280B2 (en) 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
FR2819265B1 (fr) * 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
US7150990B2 (en) * 2002-03-06 2006-12-19 Reprocell, Inc. Self-renewing pluripotent hepatic stem cells
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
WO2005047482A2 (en) 2003-11-12 2005-05-26 Xiao Xu Real time electronic cell sensing systems and applications for cell-based assays
WO2004019767A2 (en) * 2002-08-29 2004-03-11 Baylor College Of Medicine Heart derived cells for cardiac repair
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US10551371B2 (en) 2003-11-10 2020-02-04 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function
US10215748B2 (en) 2002-12-20 2019-02-26 Acea Biosciences, Inc. Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
US10539523B2 (en) 2002-12-20 2020-01-21 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
ITRM20030376A1 (it) * 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US8859273B2 (en) 2003-12-24 2014-10-14 Medtronic, Inc. Methods of using HCN genes to treat cardiac arrhythmias
BRPI0507429A (pt) * 2004-02-06 2007-06-26 Theradigm Inc composição, meio condicionado de células estromais de medula óssea, métodos de modular a expressão da molécula do complexo principal de histocompatibilidade e da molécula de mhc sobre uma nsc isolada, nsc isolada, e, dispositivo de cultura de células neurais
US20090074669A1 (en) 2004-03-31 2009-03-19 Ebert Steven N PNMT as a novel marker for progenitor cells
JP2007534946A (ja) * 2004-04-23 2007-11-29 アメリカ合衆国 幹細胞に特異的に結合するモノクローナル抗体の使用
JP4814875B2 (ja) 2004-05-11 2011-11-16 アキシオジェネシス エージー ｉｎｖｉｔｒｏ分化細胞に基づく薬物発見のための検定
JP2008506416A (ja) * 2004-07-19 2008-03-06 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 遺伝子組み換えされた細胞が合胞体の機能を変える効果を監視するための分析システム
ATE507290T1 (de) * 2004-07-27 2011-05-15 Kowa Co Zellfusionspromotor und dessen nutzung
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US20080241111A1 (en) * 2005-03-04 2008-10-02 Kyoto University Pluripotent Stem Cell Derived from Cardiac Tissue
EP1857544B1 (de) * 2005-03-04 2012-06-20 Kyoto University Aus herzgewebe stammende pluripotente stammzelle
CN103356704B (zh) * 2005-03-31 2015-09-30 斯丹姆涅恩有限公司 制备用以治疗由糖尿病性神经病引发的溃疡的药物的方法
JPWO2007010858A1 (ja) * 2005-07-15 2009-01-29 国立大学法人京都大学 骨格筋組織由来の単一細胞よりクローン化した多能性幹細胞
FR2896511B1 (fr) * 2006-01-26 2012-10-26 Centre Nat Rech Scient Procede de culture de cellules issues du tissu adipeux et leurs applications.
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
WO2008040027A2 (en) * 2006-09-28 2008-04-03 The Regents Of The University Of California Directed differentiation and maturation of stem cell-derived cardiomyocytes
WO2008043099A2 (en) 2006-10-06 2008-04-10 Medtronic, Inc. Hybrid pacing system
KR101240487B1 (ko) * 2006-11-09 2013-03-08 더 존스 홉킨스 유니버시티 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화
CA2699860A1 (en) * 2007-07-18 2009-03-26 Cellartis Ab Cardiomyocyte-like cell clusters derived from hbs cells
EP2198010A4 (de) * 2007-09-12 2010-10-06 Univ California Zusammensetzungen und verfahren zur verbesserung der funktionellen wirksamkeit von stammzellen abgeleiteter herzmuskelzellen
WO2009092005A2 (en) * 2008-01-18 2009-07-23 The J. David Gladstone Institutes Methods of generating cardiomyocytes and cardiac progenitors and compositions
WO2009120762A2 (en) 2008-03-27 2009-10-01 Mount Sinai School Of Medicine Of New York University Human cardiovascular progenitor cells
EP2291645B1 (de) 2008-05-05 2015-09-09 Acea Biosciences, Inc. Markierungsfreie überwachung der elektromechanischen kopplung und erregbaren zellen anhand von systemen auf impedanzbasis mit millisekunden-zeitauflösung
RU2662675C1 (ru) * 2009-07-09 2018-07-26 Янссен Байотек, Инк. Клетки, производные от кардиальной ткани
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
WO2011146531A1 (en) * 2010-05-18 2011-11-24 Acea Biosciences, Inc Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (rtca) cardio instruments
WO2012098260A1 (en) 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
EP3088900B1 (de) * 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin als marker für intermittierendes vorhofflimmern
EP2861238A4 (de) * 2012-06-05 2016-03-16 Capricor Inc Optimierte verfahren zur erzeugung von herzstammzellen aus herzgewebe und deren verwendung in der herztherapie
EP2882445B1 (de) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomen und mikroribonukleinsäuren zur geweberegeneration
JP6312215B2 (ja) * 2012-12-28 2018-04-18 国立大学法人京都大学 人工多能性幹細胞、心筋細胞又はその前駆細胞の製造方法
WO2014116874A1 (en) 2013-01-23 2014-07-31 Ronald Li Engineered physical alignment of stem cell-derived cardiomyocytes
US9493742B2 (en) 2013-03-15 2016-11-15 Emory University Purification of cell mixtures using molecular beacons targeting cell specific RNA
US10087436B2 (en) 2014-02-06 2018-10-02 The Regents Of The University Of California Electrophysiologically mature cardiomyocytes and methods for making same
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CN110582569B (zh) 2017-03-03 2024-04-02 安捷伦科技有限公司 用于iPSC和ESC衍生的心肌细胞的功能成熟的方法和系统
AU2018255346B2 (en) 2017-04-19 2024-05-02 Capricor Inc Methods and compositions for treating skeletal muscular dystrophy
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
USD941488S1 (en) 2020-02-07 2022-01-18 Agilent Technologies, Inc. Instrument for analyzing biological cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU8401498A (en) 1997-07-14 1999-02-10 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
EP1100870B1 (de) 1998-07-31 2008-01-02 Genzyme Corporation Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
AU5498800A (en) 1999-06-25 2001-01-31 Baylor College Of Medicine Stem cells derived from skeletal muscle
ATE514772T1 (de) 1999-08-05 2011-07-15 Abt Holding Co Multipotente erwachsene stammzellen und verfahren zu deren isolierung
AU5159901A (en) * 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

Also Published As

Publication number Publication date
AU2002337949B1 (en) 2003-05-06
EP1444329A2 (de) 2004-08-11
US20050058633A1 (en) 2005-03-17
US20030082153A1 (en) 2003-05-01
WO2003035838A3 (en) 2003-07-17
US7220582B2 (en) 2007-05-22
ATE348878T1 (de) 2007-01-15
US20070212423A1 (en) 2007-09-13
WO2003035838A2 (en) 2003-05-01
EP1444329B1 (de) 2006-12-20
CA2464088A1 (en) 2003-05-01
JP4377690B2 (ja) 2009-12-02
EP1444329A4 (de) 2004-11-24
JP2005506845A (ja) 2005-03-10

Similar Documents

Publication Publication Date Title
DE60216959D1 (de) Sich in schlagende kardiomyozyten verwandelnde stammzellen
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
NO20024200D0 (no) Serumfri dyrking av primate embryonale stamceller
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
HUP0301002A2 (hu) Kettős specifitású ellenanyagok, eljárások előállításukra és alkalmazásaik
NO20013770D0 (no) Metoder og blandinger for å öke antall hvite blodceller
ATE420945T1 (de) Chemisch definiertes medium für kultivierte säugerzellen
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
GB2393734B (en) Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
ATE426023T1 (de) ßHEDGEHOG-LIKEß PROTEINE VON WIRBELTIEREN, DIE EMBRYONALE STRUKTUREN INDUZIEREN
ATE333882T1 (de) Zusammensetzungen zur hemmung der angiogenese
DE60235836D1 (de) Ahren und verwendung davon
ATE477225T1 (de) Direkte herstellung von hochreinem fischer- tropsch-wachs
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
DE60140686D1 (de) Whisker-vermittelte transformation von embryogenen suspensionskulturen von baumwolle
ATE431416T1 (de) Enzymatische synthese von deoxyribonucleotiden
MXPA02011858A (es) Inhibidores de adhesion de celula mediada por alfabeta2.
ATE397019T1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
NO20041633L (no) Fremgangsmate for fremstilling av heparin fra mastcelle kulturer
NO20040174L (no) Fremgangsmate for donorspesifikk krysstilpasning
ATE251106T1 (de) Herstellung von carvon
SE9904749D0 (sv) Polycrystalline diamond microstructures
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren

Legal Events

Date Code Title Description
8332 No legal effect for de